Shares of Natco Pharma and Eris Lifesciences climbed strongly after both companies announced a partnership to commercialise the generic version of the diabetes and weight-management drug semaglutide in India, reflecting rising investor optimism in the fast-growing metabolic care segment. The move comes as regulatory approval has paved the way for the generic product’s launch, and markets rallied on expectations of expanding diabetes treatment demand. Natco’s shares surged across several sessions as traders priced in the outlook for a potential market share gain from this therapy. While the broader equity market faces cautious sentiment due to geopolitical concerns and foreign investor outflows, specific pharma counters like Natco and Eris are drawing fresh interest based on strategic collaborations and product pipeline expansion. Disclaimer: Investments in securities are subject to market risk. This is for educational purposes only. Investors must verify information before investing and consider their financial position & risk profile.

#WatchOutFor#StockInNews